News
- Elisigen Reports Positive Medium-Dose Results from Phase 1/2a Trial of NG101 for Wet AMD at ASRS
- Elisigen Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
- Elisigen Presents Clinical Data on Gene Therapy for wAMD, Demonstrating an 89% Reduction in Anti-VEGF Injections
- Elisigen Presents Positive 52-Week Phase 1/2a Data for NG101 at ARVO 2026; Low-Dose Cohort Shows 89% Reduction in anti-VEGF Injections in wAMD
- Elisigen Appoints Daishin Securities as IPO Underwriter, Advancing KOSDAQ Listing Preparations
- Elisigen Appoints Global Drug Development Expert Dr. Jinguk Choi
- Following Competitors’ KRW 2.6 Trillion Licensing Deal, Elisigen Pursues Global Licensing for Its AAV Gene Therapy for wAMD" [Inside Elisigen III]
- While Competing wAMD Therapies Last Only Months, NG101 Is Designed to Deliver Therapeutic Effects for at Least Five Years [Inside Elisigen II]
- An Innovative Drug Developer Backed by KDB Bank and All Three K-Bio Vaccine Funds [Inside Elisigen I]
- Elisigen Closes Series C Financing of KRW 42 Billion
- Neuracle Genetics Rebrands as 'Elisigen'
- Neuracle Genetics Announces Completion of Dosing for Phase 1/2a SENSE Study of NG101
- Neuracle Genetics Completes North American Phase 1/2a Dosing for NG101 (20 Participants)
- Neuracle Genetics Announces Positive Interim Phase 1/2a Data for NG101, Showing 91% Reduction in Treatment Burden for Patients with Wet AMD
- Neuracle Genetics' wet AMD Gene Therapy Selected for KDDF National New Drug Development Project
- Neuracle Genetics' NG101 Receives FDA Fast Track Designation and Completes Dosing for Cohort 1
- Neuracle Genetics' NG101 Granted FDA Fast Track Designation for wet AMD
- Neuracle Genetics Receives Health Canada Approval for NG101 Phase 1/2a Clinical Trial